Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation

Ong, Andrew T.L.; Hoye, Angela; Aoki, Jiro; Mieghem, Carlos A.G. van; Rodríguez-Granillo, Gastón A.; Sonnenschein, Karel; Regar, Evelyn; McFadden, Eugène; Sianos, Georgios; Giessen, Willem J. van der; Jaegere, Peter P.T. de; Feyter, Pim de; Domburg, Ron T. van; Serruys, Patrick W.

doi:10.1016/j.jacc.2004.09.079

Cited by 394 publications

(181 citation statements)

References 24 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…Afterwards, from BMS to DES, the coronary artery interventional procedure has achieved bril-liant advancements, but still issues such as thrombosis and restenosis are present. For DES, encouraging results were reported in the early-mid period clinical experiments compared to the metal stents [61]; however, the results with the concerns for late thrombosis due to the stent remaining in the body after the release of the drug are being suggested [62,63]. While there is no accurately clarified mechanism regarding the phenomenon, excessive inflammatory reaction is caused due to the drugs and healing process is blocked to cause the formation of new inner membrane.…”

Section: Resultsmentioning

confidence: 99%

Biodegradable stent

Kwon¹,

Kim²,

Kim³

et al. 2012

JBiSE

View full text Add to dashboard Cite

The bare metal stent (BMS) used in the blood vessel caused the restenosis after the operation due to formation and proliferation of neointimal. Recently, as a method to overcome the problems of BMS, drug eluting stent (DES) is developed and being applied to human body which has drug reducing restenosis applied on the metal surface. DES has the advantage of greatly reducing the restenosis after the operation; however, metal stent remains in the body after the drug is released causing issues such as late thrombosis and restenosis so that currently the attention is increasing for biodegradable materials that reduce restenosis and thrombosis by degrading as a certain amount of time passes after the drug is released by the stent material. In this review, the study trend of biodegradable stent will be explained.

show abstract

Section: Resultsmentioning

confidence: 99%

Biodegradable stent

Kwon¹,

Kim²,

Kim³

et al. 2012

JBiSE

View full text Add to dashboard Cite

show abstract

“…Az Országos Kardiológiai Intézet Prevenciós Labo ratóriumban a kardiológiai nem invazív vizsgálatok kal (27) a közepes CV rizikójú egyéneknél további rizikóstratifikációt végzünk, ill. a nagy CV rizikójú egyéneknél az atheroscleroticus elváltozások felis merésére törekszünk a korai szakban. Az eredmé nyek ismeretében a gyógyszeres és nem gyógyszeres kezelés beállítása és a beteg felvilágosítása történik.…”

Section: A Kivihetőségi Vizsgálat Eredményeinek Felhasz Nálásával Alaunclassified

Az Orvosi Hetilap 2006 októberi lapszámai

2006

View full text Add to dashboard Cite

“…Compared with a bare metal stent, a drug-eluting stent obviously reduces the occurrence rate of in-stent restenosis after PCI but increases the risk of ST. Drug-eluting stents also delay vascular endothelial healing. Incomplete endothelialization and local vascular hypersensitivity may cause late ST, which increases patient mortality by 15-45% (4,5). Thus, anti-platelet therapy should be enhanced in patients with coronary heart disease after PCI, particularly after implantation of a drug-eluting stent.…”

Section: Introductionmentioning

confidence: 99%

Investigation of standardized administration of anti-platelet drugs and its effect on the prognosis of patients with coronary heart disease

Ding

Zhang

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. The aim of the present study was to explore the effect of adherence to standardized administration of anti-platelet drugs on the prognosis of patients with coronary heart disease. A total of 144 patients newly diagnosed with coronary heart disease at Lu'an Shili Hospital of Anhui Province (Lu'an, China) between June 2010 and June 2012 were followed up. Kaplan-Meier curves and the Cox regression model were used to evaluate the effects of standardized administration of anti-platelet drugs on primary and secondary end-point events. Of the patients with coronary heart disease, 109 (76%) patients took standard anti-platelet drugs following discharge. Kaplan-Meier curve and Cox regression analysis showed that standardized administration of anti-platelet drugs reduced the risk of primary end-point events (including all-cause mortality, non-lethal myocardial infarction and stroke) of patients with coronary heart disease [hazard ratio (HR)=0.307; 95% confidence interval (CI): 0.099-0.953; P=0.041) and all-cause mortality (HR=0.162; 95% CI: 0.029-0.890; P=0.036); however, standardized administration had no predictive value with regard to secondary end-point events. Standardized administration of anti-platelet drugs obviously reduced the risk of primary end-point events in patients with coronary heart disease, and further analysis showed that only all-cause mortality exhibited a statistically significant reduction.

show abstract

Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation

Abstract: The unrestricted use of SES or PES is associated with ST rates in the range expected for BMS. Stent thrombosis was associated with a high morbidity and mortality. Bifurcation stenting, when performed in patients with acute myocardial infarction, was associated with an increased risk of ST.

Cited by 394 publications

References 24 publications

Biodegradable stent

Biodegradable stent

Az Orvosi Hetilap 2006 októberi lapszámai

Investigation of standardized administration of anti-platelet drugs and its effect on the prognosis of patients with coronary heart disease

Contact Info

Product

Resources

About